Piramal Pharma Limited Announces Q3 and 9M FY26 Results with Revenue from Operations at ₹ 2,140 Crores and ₹ 6,117 Crores respectively

Piramal Pharma Limited, a leading global pharmaceutical, health and wellness company, announced its standalone and consolidated results for the Third Quarter (Q3) and Nine Month (9M) ended 31° December 2025. The company reported a revenue from operations of ₹ 2,140 Crores for Q3FY26 and ₹ 6,117 Crores for 9MFY26. The CDMO segment reported a revenue of ₹ 1,166 Crores for Q3FY26 and ₹ 3,207 Crores for 9MFY26. The CHG segment reported a revenue of ₹ 668 Crores for Q3FY26 and ₹ 1,948 Crores for 9MFY26. The PCH segment reported a revenue of ₹ 334 Crores for Q3FY26 and ₹ 954 Crores for 9MFY26. The company also announced the acquisition of Kenalog®, a branded commercial injectable product with complex manufacturing requirements, from Bristol-Myers Squibb.